



Radiopharm and TerraPower sign supply agreement for Actinium-225

Collaboration gives Radiopharm Theranostics access to rare medical isotope for clinical trials in areas of high unmet medical need

SYDNEY, Australia and BELLEVUE, Washington – January 31st, 2022 - Radiopharm Theranostics (ASX: RAD) and TerraPower, a leading nuclear innovation company, today announced an agreement that will help advance the next generation of radiopharmaceutical therapies for cancer treatment.

“There is tremendous growth projected for radiopharmaceutical therapies over the next 5-10 years, when you can combine the right molecule with the right Isotope in areas of high unmet medical needs. Access to high quality Actinium-225 allows us to accelerate the clinical development of our broad pipeline,” said Riccardo Canevari, CEO and managing Director of Radiopharm. “We are privileged to be a part of this journey as we work with TerraPower to transform outcomes for patients suffering for oncological diseases”

“Through our TerraPower Isotopes® work, we harness our focus on nuclear science and innovation and apply it to the health care sector to enable the development of targeted and potentially lifesaving cancer treatments,” said Scott Claunch, president of TerraPower Isotopes. “Our collaboration with Radiopharm Theranostics aligns with our vision to provide broad industry access to Actinium-225, enabling partners to develop much-needed radiopharmaceuticals.”

Since 2018, TerraPower has been working to increase the supply of Actinium-225 from Thorium-229 decay, which is derived from Uranium-233 managed by the U.S. Department of Energy. Actinium-225 is an alpha-emitting radionuclide with significant promise in effectively treating cancer patients. It can be attached to a targeting molecule, which will then selectively target and destroy cancerous tissue.

Under this agreement, TerraPower’s subsidiary, TerraPower Isotopes, LLC, will supply Actinium-225 to Radiopharm Theranostics. The Actinium-225 will be utilized in drug trials involving targeted alpha therapy in multiple disease areas.

Additional Disclosures

The effective date of the supply agreement is 31 January 2022 and there are no material preconditions. The supply agreement is for an initial period of three years and may be extended for a further two successive one-year periods unless agreed otherwise by either parties. Cancellation provisions are at industry standard rates.

All data generated and all inventions and discoveries made or conceived from the clinical trials shall be the property of Radiopharm as client of TerraPower.

**ASX ANNOUNCEMENT
1 FEBRUARY 2022**

About TerraPower

TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. Learn more at terrapower.com.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (ticker: RAD) since November 2021. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be First to Market or Best in Class. The clinical program includes five Phase 2 and two Phase 1 trials in a variety of solid tumor cancers including breast, kidney and brain, with a total of 156 patients dosed to date. Learn more at radiopharmtheranostics.com.

###

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>